Skip to content

Effect of a Test Food on Information Processing and Its Safety

Effect of a Test Food on Information Processing and Its Safety - Effect of a Test Food on Information Processing and Its Safety

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000031094
Enrollment
100
Registered
2018-02-01
Start date
2018-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N/A(healthy adults)

Interventions

24 weeks) Oral intake of the placebo product (4 capsules one time in a day
24 weeks)

Sponsors

TES Holdings Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Japanese males and females aged 35-54 years. 2)Individuals being healthy and are not suffered from a chronic malady. 3)Individuals having healthy cognitive function. 4)Individuals having self-awareness of disability of information processing. 5)Individuals whose written informed consent has been obtained. 6)Individuals who can come to the designated venue for this study and be inspected. 7)Individuals judged appropriate for the study by the principal.

Exclusion criteria

Exclusion criteria: 1)Individuals using medical products. 2)Individuals using a drug to treat a disease. 3)Individuals having cognitive impairment or mild cognitive impairment. 4)Individuals having visually impairment or hearing impairment. 5)Individuals who used psychotropic drugs in the past 1 month. 6)Individuals having a history of surgery for stroke, subarachnoid hemorrhage, cerebral infarction, cerebral hemorrhage, head trauma. 7)Individuals being patient or have a history of hypertension, hyperlipidemia and diabetes. 8)Individuals being patient or have a history of heart failure, kidney failure, and hepatitis B or C. 9)Individuals being patient or have a history of serious hepatopathy, kidney damage, heart disease, lung disease and hematological disease. 10)Individuals being a patient or have a history of endocrine disease. 11)Individuals whose BMI is over 30 kg/m2. 12)Individuals taking alcohol excessively (expressed in an amount of alcohol: over 60g/day). 13)Individuals whose average number of cigarettes for smoking is over 21/day. 14)Individuals with serious anemia. 15)Individuals being sensitive to test product or other foods, and medical products. 16)Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements with similar efficacy to test product in the past 3 months or will ingest those foods during the test period. 17)Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements containing active ingredient of the test product in the past 3 months or will ingest those foods during the test period. 18)Individuals with possible changes of life style, such as conducting a long-term travel, during the test period. 19)Individuals who participated in other clinical studies in the past 3 months. 20)Individuals being or whose family is engaged in healthy or functional foods. 21)Individuals judged inappropriate for the study by the principal.

Design outcomes

Primary

MeasureTime frame
[1]Wechsler Adult Intelligence Scale - Third Edition (Week 0, Week 24).

Secondary

MeasureTime frame
*Secondary outcomes [1]SF-36v2, Japanese version (Week 0, Week 12, Week 24) [2]Questionnaire of physical feeling (Week 12, Week 24) *Safety evaluation [1]Blood pressure, pulsation (Week 0, Week 12, Week 24) [2]Weight, body fat percentage, BMI (Week 0, Week 12, Week 24) [3]Doctor's questions (Week 0, Week 12, Week 24) [4]Subject's diary (each day during the test period) *Other index [1]Mini Mental State Examination (Week 0)

Countries

Japan

Contacts

Public ContactRyoma Shimizu

TES Holdings Co., Ltd Administrative Department of Clinical Trials

r.shimizu@tes-h.co.jp03-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026